Aug 12, 2025 5:30pm EDT Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Aug 05, 2025 7:00am EDT GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Jun 25, 2025 6:15pm EDT Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Apr 17, 2025 7:00am EDT Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Apr 07, 2025 7:00am EDT Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Mar 14, 2025 7:00am EDT Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Feb 24, 2025 7:00am EST Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Feb 05, 2025 5:30pm EST Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
